Výsledky vyhledávání - Jaume Capdevila
- Zobrazuji výsledky 1 - 20 z 66
- Přejít na další stránku
-
1
-
2
GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours Autor Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande
Vydáno 2014Revisão -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors Autor Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, Anne Couvelard, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar
Vydáno 2022Revisão -
11
Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies Autor Enrique Grande, Michael C. Kreißl, Sébastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke Kjær Tolstrup, José Luís Zamorano, Jaume Capdevila
Vydáno 2013Revisão -
12
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in dev... Autor Rocio García‐Carbonero, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, Isabel Sevilla, Àlex Teulé, María Quindós, Enrique Grande, Jaume Capdevila, Javier Aller, Javier Arbizu, Paula Jiménez‐Fonseca
Vydáno 2015Revisão -
13
-
14
Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Autor Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier
Vydáno 2014Artigo -
15
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results Autor Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, Ulrich F. Pape, Jaume Capdevila, Francesco Panzuto, Xuan-Mai Truong Thanh, Aude Houchard, Philippe Ruszniewski
Vydáno 2021Artigo -
16
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer Autor Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara
Vydáno 2016Artigo -
17
Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer Autor Lori J. Wirth, Marcia S. Brose, Rossella Elisei, Jaume Capdevila, Ana O. Hoff, Mimi I. Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Xia Meng, Patricia Maeda, Eric J. Sherman
Vydáno 2022Artigo -
18
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors Autor Massimo Falconi, Barbro Eriksson, Gregory Kaltsas, Detlef K. Bartsch, Jaume Capdevila, Martyn Caplin, Beata Kos‐Kudła, Dik J. Kwekkeboom, Guido Rindi, Günter Klöppel, Nicholas S. Reed, Réza Kianmanesh, Robert T. Jensen
Vydáno 2016Artigo -
19
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer Autor Garazi Serna, Fiorella Ruíz‐Pace, Jorge Hernando, Lidia Alonso, Roberta Fasani, Stefania Landolfi, Raquel Comas, José Jiménez, Elena Élez, Susan Bullman, Josep Tabernero, Jaume Capdevila, Rodrigo Dienstmann, Paolo Nucíforo
Vydáno 2020Artigo -
20
A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors Autor Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, R.E. Knoblauch, Sen Hong Zhuang
Vydáno 2011Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Oncology
Cancer
Neuroendocrine tumors
Biology
Gastroenterology
Colorectal cancer
Chemotherapy
Surgery
Thyroid cancer
Cancer research
Clinical endpoint
Clinical trial
Confidence interval
Pathology
Randomized controlled trial
Adverse effect
Chemoradiotherapy
Hazard ratio
Environmental health
Gene
Genetics
Population
Thyroid
Alternative medicine
Hormone
Lenvatinib
Placebo
Radiation therapy